Bristol-myers Squibb Compnay

Bristol-myers Squibb

Kumar Balashanmuga Pabbisetty

Andrew K Dilger

Donald J P Pinto

Wu Yang

Leon M Smith, Ii

William R Ewing

James R Corte

Michael J Orwat

Yufeng Wang

Tianan Fang

Yeheng Zhu

Indawati De Lucca

Ruth Richmond Wexler

Scott A Shaw

Paul Joseph Gilligan

Peter W Glunz

Nicholas Ronald Wurtz

Ellen K Kick

Manoranjan Panda

Vladimir Ladziata

Andrew Quoc Viet

Donald Jp Pinto

Leon M Smith

Sutjano Jusuf

Meriah Neissel Valente

Benjamin P Vokits

Indawati DeLucca

Leon M Smith Ii

Donald JP Pinto

Leon M Ii Smith

Donald JP Pinto Pinto

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Pyrimidinones as factor XIA inhibitors

The present invention provides compounds of Formula (1): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

Spiroheptane salicylamides and related compounds as inhibitors of ROCK

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. 

Spiroheptane salicylamides and related compounds as inhibitors of rock

Pyrimidinones as factor XIa inhibitors

The present invention provides compounds of Formula (I): wherein A, Y and Rare each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments. 

Triazolopyridine inhibitors of myeloperoxidase

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties

The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Macrocyclic factor XIa inhibitors bearing heterocyclic groups

The present invention provides compounds of Formula (V):  or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

Dihydropyridone P1 as factor XIa inhibitors

The present invention provides compounds of Formula (I): wherein A and Rare each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments. 

Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

Macrocycles with aromatic P2' groups as factor xia inhibitors

The present invention provides compounds of Formula (X):(Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. 

Dihydropyridone p1 as factor XIa inhibitors

Growing community of inventors

Piscataway, NJ, United States of America

Kumar Balashanmuga Pabbisetty